{"id":"NCT00433199","sponsor":"Abbott","briefTitle":"Testosterone Treatment for Hypogonadal Men","officialTitle":"A Multi-Center, Randomized, Double-Blind,Placebo-Controlled Efficacy and Safety Study of Testosterone Gel 1.62% for the Treatment of Hypogonadal Men","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-02","primaryCompletion":"2007-10","completion":"2008-04","firstPosted":"2007-02-09","resultsPosted":"2011-12-08","lastUpdate":"2015-01-27"},"enrollment":274,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypogonadism"],"interventions":[{"type":"DRUG","name":"Testosterone (T) Gel 1.62%","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"T-Gel 1.62%","type":"EXPERIMENTAL"}],"summary":"Demonstrate efficacy and safety of Testosterone Gel 1.62% for the treatment of hypogonadal men","primaryOutcome":{"measure":"Percentage of Subjects on Testosterone Treatment Achieving Target Range for Testosterone Cav (Time-averaged Concentration Over the Dosing Interval of 24 Hours) on Day 112","timeFrame":"Day 112","effectByArm":[{"arm":"T-Gel 1.62%","deltaMin":81.6,"sd":null},{"arm":"Placebo","deltaMin":37,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["22321357"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":40},"commonTop":["Cell marker procedures","Upper respiratory tract infections","Headaches NEC","Bacterial infections NEC"]}}